Ocular Therapeutix Declares Results on Glaucoma

Ocular Therapeutix, Inc. introduced preliminary results of their sustained release travoprost-loaded punctum plug feasibility survey regarding the remedy for glaucoma. This travoprost punctum plug (OTX-TP1) seemed to be evaluated for the reduction of heightened intraocular strain in subjects along with open-angle glaucoma or ocular hypertension over a thirty-day period.

Twenty six eyes were really treated in 17 affected individuals at the Singapore National Eye Center and of course the National University Hospital in Singapore. Just before the insertion of the plugs, mean intraocular pressure at baseline for the study group appeared to be recorded at 26.3 mm Hg. Intraocular pressure (IOP) dropped by 5.5 mm Hg at day-3 post-insertion, and after one month of treatment, mean IOP appeared to be 6.5 mm Hg below baseline. The OTX-TP1 is designed to absorb in about 4 to 6 weeks, and 88% of plug were really present at the day-30 visit. Plugs last in the nasolacrimal canal on day 30 were discharged. One affected person demonstrated extreme tearing. Apart from that, there were no visual complaints outside normal confines, and affected individuals were cozy overall.

Results are similar to topical trusted brand name ophthalmic solutions, Travatan, Lumigan, and Xalatan. However, topical groups are plagued along with problems with non-compliance, which can lead to expensive and invasive surgeries, vision impairment, in addition to blindness. It really has been reported that up to 60% of affected individuals tend not to administer ophthalmic drops as organized, although patients' perception is the fact that they are compliants along with 97% of their total dosing. Sustained release travoprost punctum plugs could help to circumvent these problems of affected person non-compliance by eliminating the demand for daily dosing.

"This product has the ability to universally alter the way our team treats glaucoma," stated Shamira Perera, M.D., Principal Investigator at the Singapore National Eye Center. "Sustained release therapy could probably a top-rated to elderly affected individuals who have problems with administering drops, could possibly help alleviate problems with non-compliance, and may possibly be favourable to anyone clinically determined with glaucoma who may prefer a lifestyle without having the inconvenience of taking drops daily."